ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities

Sep 11, 2023

ImmunityBio Names Enrique Diloné as Chief Technology Officer

Aug 03, 2023

ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors

Jul 20, 2023

Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients

Jul 10, 2023

ImmunityBio to Participate in the Jefferies Global Healthcare Conference

May 22, 2023

National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome

Apr 25, 2023

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University

Apr 24, 2023

ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU

Feb 16, 2023

ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors

Feb 15, 2023

ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration

Jan 19, 2023